Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease

Exclusion criteria

• ✕. Other idiopathic parkinsonian syndromes, e.g., Progressive Supranuclear Palsy, Cortico-basal syndrome, or Multiple System Atrophy
• ✕. Secondary parkinsonian syndromes (drug-induced, traumatic, encephalitic or vascular)
• ✕. Change in antiparkinsonian medication one month prior to enrolment
• ✕. Prior use of glycopyrrolate with or without known hypersensitivity will be considered an exclusion criterion, as it increases the risk of unblinding due to prior knowledge of potential side effects or therapeutic benefit
• ✕. Change in the dose one month prior to enrolment of other anticholinergic agents or other drugs potentially affecting saliva production, such as tricyclic antidepressants, MAO-A inhibitors, neuroleptics (including clozapine and quetiapine more frequently used in PD) or hypnotics. These medication will remain in a constant dose throughout the trial;
• ✕. Concomitant use of solid oral dosage forms of potassium chloride;
• ✕. Pregnancy, breastfeeding, and premenopausal females or males not using adequate contraception; medically acceptable birth control methods for this study include: (1) Abstinence (no sexual intercourse); (2) Intrauterine device (IUD); (3) Diaphragm with spermicide; (4) Condom with spermicide; and (5) Oral contraceptives (birth control pills) + condom/diaphragm with spermicide.
• ✕. Moderate-to-severe constipation in spite of optimal treatment (MDS-UPDRS, item 1.11\>2);